A Phase 1b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Pharmacodynamics and Safety of HGS1025, a Human Monoclonal Anti-CCR5 Antibody, in Subjects With Ulcerative Colitis.

Trial Profile

A Phase 1b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Pharmacodynamics and Safety of HGS1025, a Human Monoclonal Anti-CCR5 Antibody, in Subjects With Ulcerative Colitis.

Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 01 Aug 2013

At a glance

  • Drugs Anti-CCR5 monoclonal antibody (Primary)
  • Indications Ulcerative colitis
  • Focus Adverse reactions; Biomarker; Pharmacodynamics
  • Most Recent Events

    • 30 Oct 2012 Trial association and lead trial centre changed from Human Genome Sciences to GlaxoSmithKline as Human Genome Sciences is acquired by GlaxoSmithKline.
    • 05 Dec 2011 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
    • 19 Sep 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top